Cargando…
New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
Cerebrospinal fluid (CSF) biomarkers based on the core pathological proteins associated with Alzheimer’s disease (AD), i.e., amyloid-β (Aβ) and tau protein, are widely regarded as useful diagnostic biomarkers. However, a lack of biomarkers for monitoring the treatment response and indexing clinical...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210893/ https://www.ncbi.nlm.nih.gov/pubmed/32284537 http://dx.doi.org/10.1038/s12276-020-0418-9 |
_version_ | 1783531351587160064 |
---|---|
author | Park, Sun Ah Han, Song Mi Kim, Chae Eun |
author_facet | Park, Sun Ah Han, Song Mi Kim, Chae Eun |
author_sort | Park, Sun Ah |
collection | PubMed |
description | Cerebrospinal fluid (CSF) biomarkers based on the core pathological proteins associated with Alzheimer’s disease (AD), i.e., amyloid-β (Aβ) and tau protein, are widely regarded as useful diagnostic biomarkers. However, a lack of biomarkers for monitoring the treatment response and indexing clinical severity has proven to be problematic in drug trials targeting Aβ. Therefore, new biomarkers are needed to track non-Aβ and non-tau pathology. Many proteins involved in the pathophysiological progression of AD have shown promise as new biomarkers. Neurodegeneration- and synapse-related biomarkers in CSF (e.g., neurofilament light polypeptide [NFL], neurogranin, and visinin-like protein 1) and blood (e.g., NFL) aid prediction of AD progress, as well as early diagnosis. Neuroinflammation, lipid dysmetabolism, and impaired protein clearance are considered important components of AD pathophysiology. Inflammation-related proteins in the CSF, such as progranulin, intercellular adhesion molecule 1, and chitinase-3-like protein 1 (YKL-40), are useful for the early detection of AD and can represent clinical severity. Several lipid metabolism-associated biomarkers and protein clearance-linked markers have also been suggested as candidate AD biomarkers. Combinations of subsets of new biomarkers enhance their utility in terms of broadly characterizing AD-associated pathological changes, thereby facilitating precise selection of susceptible patients and comprehensive monitoring of the treatment response. This approach could facilitate the development of effective treatments for AD. |
format | Online Article Text |
id | pubmed-7210893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-72108932020-05-18 New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease Park, Sun Ah Han, Song Mi Kim, Chae Eun Exp Mol Med Review Article Cerebrospinal fluid (CSF) biomarkers based on the core pathological proteins associated with Alzheimer’s disease (AD), i.e., amyloid-β (Aβ) and tau protein, are widely regarded as useful diagnostic biomarkers. However, a lack of biomarkers for monitoring the treatment response and indexing clinical severity has proven to be problematic in drug trials targeting Aβ. Therefore, new biomarkers are needed to track non-Aβ and non-tau pathology. Many proteins involved in the pathophysiological progression of AD have shown promise as new biomarkers. Neurodegeneration- and synapse-related biomarkers in CSF (e.g., neurofilament light polypeptide [NFL], neurogranin, and visinin-like protein 1) and blood (e.g., NFL) aid prediction of AD progress, as well as early diagnosis. Neuroinflammation, lipid dysmetabolism, and impaired protein clearance are considered important components of AD pathophysiology. Inflammation-related proteins in the CSF, such as progranulin, intercellular adhesion molecule 1, and chitinase-3-like protein 1 (YKL-40), are useful for the early detection of AD and can represent clinical severity. Several lipid metabolism-associated biomarkers and protein clearance-linked markers have also been suggested as candidate AD biomarkers. Combinations of subsets of new biomarkers enhance their utility in terms of broadly characterizing AD-associated pathological changes, thereby facilitating precise selection of susceptible patients and comprehensive monitoring of the treatment response. This approach could facilitate the development of effective treatments for AD. Nature Publishing Group UK 2020-04-13 /pmc/articles/PMC7210893/ /pubmed/32284537 http://dx.doi.org/10.1038/s12276-020-0418-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Park, Sun Ah Han, Song Mi Kim, Chae Eun New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease |
title | New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease |
title_full | New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease |
title_fullStr | New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease |
title_full_unstemmed | New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease |
title_short | New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease |
title_sort | new fluid biomarkers tracking non-amyloid-β and non-tau pathology in alzheimer’s disease |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210893/ https://www.ncbi.nlm.nih.gov/pubmed/32284537 http://dx.doi.org/10.1038/s12276-020-0418-9 |
work_keys_str_mv | AT parksunah newfluidbiomarkerstrackingnonamyloidbandnontaupathologyinalzheimersdisease AT hansongmi newfluidbiomarkerstrackingnonamyloidbandnontaupathologyinalzheimersdisease AT kimchaeeun newfluidbiomarkerstrackingnonamyloidbandnontaupathologyinalzheimersdisease |